Tregalizumab Biosimilar - Research Grade

Human

CD4

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-CD4 (GK1.5) In Vivo Antibody - Low Endotoxin (ICH1042), Bulk Anti-Human CD4 (OKT-4) Antibody (ICH1166), Anti-Mouse CD4 (YTS191) In Vivo Antibody - Low Endotoxin (ICH1210), Anti-Rat CD4 (OX-38) In Vivo Antibody - Low Endotoxin (ICH1255), Ibalizumab Biosimilar - Research Grade (ICH5029), Clenoliximab Biosimilar - Research Grade (ICH5193), Cedelizumab Biosimilar - Research Grade (ICH5430), Keliximab Biosimilar - Research Grade (ICH5616), Priliximab Biosimilar - Research Grade (ICH5788), Semzuvolimab Biosimilar - Research Grade (ICH5851)

https://www.imgt.org/mAb-DB/

ICH3002

P01730

Blue ice

ichor.bio ICH5942 is a research-grade biosimilar of tregalizumab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. Tregalizumab (originally BT-061) is a humanized IgG1 kappa monoclonal antibody directed against human CD4. Unlike conventional anti-CD4 antibodies, it is non-depleting and was developed as a regulatory T cell (Treg) agonist: it recognizes a distinct conformational epitope and selectively boosts the suppressive activity of Tregs without broadly activating effector T cells, a mechanism explored for autoimmune indications such as rheumatoid arthritis. This biosimilar reproduces the target specificity of the originator and is built around the CD4 antigen rather than around a hybridoma clone. It is intended for functional and in-vitro applications: CD4 binding assays, epitope and competition studies, Treg activation readouts, and use as a reference or benchmarking control alongside other anti-CD4 reagents. Material is offered as low-endotoxin, research-grade protein suitable for bulk milligram-to-gram scale. It is not a clinical drug and is not intended for therapeutic or diagnostic use. Lot-specific characterization data are available on request. CD4 (UniProt P01730) is a single-pass type I transmembrane glycoprotein of the immunoglobulin superfamily, composed of four extracellular domains (D1-D4), and is expressed on helper and regulatory T cells, thymocytes, and subsets of monocytes and dendritic cells. As a co-receptor, CD4 binds MHC class II molecules on antigen-presenting cells and stabilizes the T-cell receptor interaction, recruiting the tyrosine kinase Lck through its cytoplasmic tail to nucleate proximal TCR signaling. This role makes CD4 central to helper T cell priming, cytokine production, and the maintenance of immune tolerance via regulatory T cells. CD4 is also the primary entry receptor for HIV-1. Tregalizumab targets a specific conformational epitope on CD4 domain 2, distinct from sites bound by conventional anti-CD4 antibodies, which underlies its selective, non-depleting activation of Treg suppressive function.

CD4, CD4mut, CD4 molecule, OKT4D, IMD79

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks